Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | SCD | O00767 | 1/20 | 0.40 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.39 |
| ▸ | HTR6 | P50406 | 7/20 | 0.38 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.38 |
| ▸ | MET | P08581 | 1/20 | 0.37 |
| ▸ | WNT1 | P04628 | 1/20 | 0.37 |
| ▸ | GSK3B | P49841 | 1/20 | 0.37 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.36 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.35 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.35 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.35 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.35 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3506204 | 0.81 | BRD4 (0.40) | SCDROCK2HTR6PIK3CAMET | |
| SCHEMBL3509001 | 0.80 | CYP2C19 (0.51) | CYP2C19HTR6METWNT1GSK3B | |
| SCHEMBL14049072 | 0.78 | HTR6 (0.40) | SCDROCK2HTR6PIK3CASCN9A | |
| SCHEMBL13746209 | 0.78 | HTR6 (0.40) | SCDROCK2HTR6PIK3CASCN9A | |
| SCHEMBL3505606 | 0.78 | BRD4 (0.39) | SCDROCK2HTR6PIK3CAWNT1 | |
| SCHEMBL18572538 | 0.77 | HDAC3 (0.45) | CYP2C19HTR6L3MBTL1POLBMEN1 | |
| SCHEMBL3327691 | 0.76 | CYP2C19 (0.45) | CYP2C19HTR6PIK3CAMETL3MBTL1 | |
| SCHEMBL1962898 | 0.76 | CYP2C19 (0.46) | CYP2C19L3MBTL1 | |
| SCHEMBL25445548 | 0.75 | ROCK2 (0.56) | SCDROCK2 | |
| SCHEMBL16697663 | 0.75 | HTR6 (0.47) | SCDHTR6L3MBTL1SCN9AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2211620-B1 | 3-PYRAZIN SUBSTITUTED PYRROLO[2,3-b]PYRIDINES AS JANUS KINASE INHIBITORS FOR THE TREATMENT OF CANCER DISEASES | MERCK SHARP & DOHME (US) | 2013-12-25 | — | — | EP | disclosed |
| US-8183245-B2 | Pyrazine substituted pyrrolopyridines as inhibitors of JAK and PDK1 | MERCK SHARP & DOHME CORP. (US) | 2012-05-22 | — | — | US | disclosed |
| US-20100210623-A1 | THERAPEUTIC COMPOUNDS | MERCK SHARP & DOHME CORP. | 2010-08-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100210623-A1 | THERAPEUTIC COMPOUNDS | JAK2, PDK1, JAK3 | CYP2C19 4202/4885SCD 3135/4885ROCK2 652/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.